Symbols / ONCO $0.51 -1.32%
ONCO Chart
About
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products; and with Immunovia AB for the development, manufacturing, and commercialization of the PancreaSure test. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was founded in 2018 and is headquartered in Cincinnati, Ohio.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 791.35K |
| Enterprise Value | -3.32M | Income | -15.53M | Sales | 815.37K |
| Book/sh | 10.11 | Cash/sh | 1.46 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | 0.00 | Forward P/E | -0.60 | PEG | — |
| P/S | 0.97 | P/B | 0.05 | P/C | — |
| EV/EBITDA | 0.53 | EV/Sales | -4.08 | Quick Ratio | 0.61 |
| Current Ratio | 0.66 | Debt/Eq | 0.31 | LT Debt/Eq | — |
| EPS (ttm) | 1229.73 | EPS next Y | -0.85 | EPS Growth | — |
| Revenue Growth | -57.40% | Earnings | 2023-11-17 17:00 | ROA | -14.93% |
| ROE | -115.46% | ROIC | — | Gross Margin | 77.62% |
| Oper. Margin | -4.22% | Profit Margin | 0.00% | Shs Outstand | 1.56M |
| Shs Float | 3.28M | Short Float | 2.99% | Short Ratio | 0.10 |
| Short Interest | — | 52W High | 14.88 | 52W Low | 0.44 |
| Beta | 3.52 | Avg Volume | 335.47K | Volume | 70.15K |
| Target Price | — | Recom | None | Prev Close | $0.52 |
| Price | $0.51 | Change | -1.32% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.52
Latest analyst target
3. DCF / Fair value
$-52.03
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.52
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2023-09-13 | down | Maxim Group | Buy → Hold | — |
| 2023-04-26 | main | HC Wainwright & Co. | — → Buy | $9 |
| 2023-02-01 | reit | HC Wainwright & Co. | — → Buy | $7 |
| 2022-12-09 | init | HC Wainwright & Co. | — → Buy | $7 |
| 2022-12-08 | init | Maxim Group | — → Buy | $4 |
- Onconetix (NASDAQ: ONCO) 10-K flags going concern risk and major Realbotix reverse merger - Stock Titan Fri, 13 Mar 2026 20
- Onco-Innovations Raises $1.22 Million in Completed Private Placement - TipRanks hu, 12 Mar 2026 21
- Onco-Innovations raises $1,215,500 with 3-year share warrants - Stock Titan hu, 12 Mar 2026 21
- XBOT: ONCO acquires RealLLC in an all-stock deal, with Realbotix gaining majority ONCO ownership - TradingView Fri, 13 Feb 2026 08
- Onconetix announces financing through private placement, debt settlement - Yahoo Finance Sat, 27 Sep 2025 07
- Onconetix, Inc. Announces Approval of 1-for-85 Reverse Stock Split by Stockholders - Nasdaq Wed, 11 Jun 2025 07
- Onconetix Announces Financing Through a $12.9 Million - GlobeNewswire Fri, 26 Sep 2025 07
- Onconetix and Ocuvex Therapeutics announce definitive merger agreement - Investing.com Wed, 16 Jul 2025 07
- symbol__ Stock Quote Price and Forecast - CNN Sat, 23 Dec 2023 19
- A Look At The Fair Value Of Oncopeptides AB (publ) (STO:ONCO) - simplywall.st Mon, 28 Jul 2025 07
- Mall greeters and TV guests: Realbotix robots to reshape Onconetix strategy - Stock Titan hu, 12 Feb 2026 08
- Onconetix Shareholders Approve Flexible Reverse Stock Split Plan - TipRanks Mon, 09 Feb 2026 08
- Onconetix Signs Share Exchange Agreement With Realbotix - TradingView hu, 12 Feb 2026 08
- Veru settles $8.8 million debt with Onconetix for cash, preferred stock, and warrants - Investing.com Fri, 26 Sep 2025 07
- Breaking: $2.1B Biotech Merger Collapses - Onconetix and Ocuvex Part Ways as Ocuvex Preps Drug Launch - Stock Titan Fri, 26 Sep 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 618 | — | — | Stock Award(Grant) at price 0.00 per share. | TARSH SIMON | Director | — | 2025-08-15 00:00:00 | D |
| 1 | 618 | — | — | Stock Award(Grant) at price 0.00 per share. | RAMDEEN TIMOTHY R. | Director | — | 2025-08-15 00:00:00 | D |
| 2 | 618 | — | — | Stock Award(Grant) at price 0.00 per share. | MEIER THOMAS PH.D. | Director | — | 2025-08-15 00:00:00 | D |
| 3 | 618 | — | — | Stock Award(Grant) at price 0.00 per share. | OAKLEY ANDREW J. | Director | — | 2025-08-15 00:00:00 | D |
| 4 | 1709 | — | — | Stock Award(Grant) at price 0.00 per share. | OAKLEY ANDREW J. | Director | — | 2025-03-21 00:00:00 | D |
| 5 | 177462 | — | — | Stock Award(Grant) at price 0.00 per share. | BRUHLMANN CHRISTIAN | Officer | — | 2024-12-20 00:00:00 | D |
| 6 | 177462 | — | — | Stock Award(Grant) at price 0.00 per share. | SCHIESS RALPH | Chief Executive Officer | — | 2024-12-20 00:00:00 | D |
| 7 | 3318 | — | — | Stock Award(Grant) at price 0.00 per share. | SAPIRSTEIN JAMES E | Director | — | 2024-09-26 00:00:00 | D |
| 8 | 3318 | — | — | Stock Award(Grant) at price 0.00 per share. | TARSH SIMON | Director | — | 2024-09-26 00:00:00 | D |
| 9 | 3318 | — | — | Stock Award(Grant) at price 0.00 per share. | RAMDEEN TIMOTHY R. | Director | — | 2024-09-26 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -785.72K | -6.32K | 0.00 | 0.00 |
| TaxRateForCalcs | 0.02 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -12.69M | -17.94M | -13.47M | -3.41M |
| TotalUnusualItems | -44.91M | -18.77M | 61.41K | |
| TotalUnusualItemsExcludingGoodwill | -44.91M | -18.77M | 61.41K | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -58.69M | -37.41M | -13.42M | -3.42M |
| ReconciledDepreciation | 731.35K | 43.94K | 6.75K | 4.89K |
| ReconciledCostOfRevenue | 1.47M | 1.19M | 0.00 | |
| EBITDA | -57.60M | -36.71M | -13.41M | -3.41M |
| EBIT | -58.33M | -36.75M | -13.42M | -3.42M |
| NetInterestIncome | -1.41M | -671.62K | 0.00 | 0.00 |
| InterestExpense | 1.41M | 671.62K | 0.00 | |
| InterestIncome | 18.00 | 0.00 | 0.00 | |
| NormalizedIncome | -14.57M | -18.65M | -13.48M | -3.42M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -58.69M | -37.41M | -13.42M | -3.42M |
| TotalExpenses | 12.86M | 17.91M | 13.48M | 3.42M |
| TotalOperatingIncomeAsReported | -56.49M | -36.03M | -13.48M | -3.42M |
| DilutedAverageShares | 32.30K | 5.03K | 3.61K | 3.21K |
| BasicAverageShares | 32.30K | 5.03K | 3.61K | 3.21K |
| DilutedEPS | -1.82K | -7.43K | -3.74K | -1.26K |
| BasicEPS | -1.82K | -7.43K | -3.74K | -1.26K |
| DilutedNIAvailtoComStockholders | -58.90M | -37.41M | -13.52M | -4.04M |
| NetIncomeCommonStockholders | -58.90M | -37.41M | -13.52M | -4.04M |
| PreferredStockDividends | 206.40K | 96.36K | 627.39K | |
| NetIncome | -58.69M | -37.41M | -13.42M | -3.42M |
| NetIncomeIncludingNoncontrollingInterests | -58.69M | -37.41M | -13.42M | -3.42M |
| NetIncomeContinuousOperations | -58.69M | -37.41M | -13.42M | -3.42M |
| TaxProvision | -1.05M | -12.59K | 0.00 | |
| PretaxIncome | -59.74M | -37.42M | -13.42M | -3.42M |
| OtherIncomeExpense | -48.00M | -18.90M | 61.41K | |
| OtherNonOperatingIncomeExpenses | -3.09M | -134.10K | ||
| SpecialIncomeCharges | -46.16M | -18.68M | 0.00 | |
| OtherSpecialCharges | 490.00K | |||
| WriteOff | 3.53M | 18.19M | 0.00 | |
| ImpairmentOfCapitalAssets | 42.63M | 0.00 | ||
| GainOnSaleOfSecurity | 1.25M | -91.97K | 61.41K | |
| NetNonOperatingInterestIncomeExpense | -1.41M | -671.62K | 0.00 | 0.00 |
| InterestExpenseNonOperating | 1.41M | 671.62K | 0.00 | |
| InterestIncomeNonOperating | 18.00 | 0.00 | 0.00 | |
| OperatingIncome | -10.33M | -17.85M | -13.48M | -3.42M |
| OperatingExpense | 11.39M | 16.72M | 13.48M | 3.42M |
| ResearchAndDevelopment | 154.36K | 1.95M | 4.13M | 1.33M |
| SellingGeneralAndAdministration | 11.23M | 14.77M | 9.35M | 2.09M |
| GeneralAndAdministrativeExpense | 11.23M | 14.77M | 9.35M | 2.09M |
| OtherGandA | 11.23M | 14.77M | 9.35M | 2.09M |
| GrossProfit | 1.06M | -1.13M | 0.00 | |
| CostOfRevenue | 1.47M | 1.19M | 0.00 | |
| TotalRevenue | 2.52M | 58.47K | 0.00 | 0.00 |
| OperatingRevenue | 2.52M | 58.47K | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | |
|---|---|---|---|---|
| TreasurySharesNumber | 152.00 | 152.00 | 135.00 | |
| OrdinarySharesNumber | 138.29K | 6.57K | 4.49K | 3.21K |
| ShareIssued | 138.44K | 6.72K | 4.62K | 3.21K |
| NetDebt | 8.68M | 5.18M | ||
| TotalDebt | 9.45M | 9.89M | 0.00 | |
| TangibleBookValue | -18.51M | -86.69M | 22.39M | 1.45M |
| InvestedCapital | 17.87M | 4.14M | 22.39M | 1.45M |
| WorkingCapital | -17.34M | -11.35M | 22.34M | 1.44M |
| NetTangibleAssets | -17.44M | -86.69M | 22.39M | 1.45M |
| CapitalLeaseObligations | 119.43K | 148.54K | 0.00 | |
| CommonStockEquity | 8.54M | -5.60M | 22.39M | 1.45M |
| PreferredStockEquity | 1.07M | 11.00 | ||
| TotalCapitalization | 9.61M | -5.48M | 22.39M | 1.45M |
| TotalEquityGrossMinorityInterest | 9.61M | 1.40M | 22.39M | 1.45M |
| MinorityInterest | 0.00 | 7.01M | 0.00 | |
| StockholdersEquity | 9.61M | -5.60M | 22.39M | 1.45M |
| OtherEquityInterest | -250.31K | |||
| GainsLossesNotAffectingRetainedEarnings | -2.72M | 2.38M | 0.00 | |
| TreasuryStock | 625.79K | 625.79K | 566.81K | 0.00 |
| RetainedEarnings | -115.68M | -56.79M | -19.38M | -5.96M |
| AdditionalPaidInCapital | 127.83M | 49.43M | 42.33M | 7.40M |
| CapitalStock | 1.07M | 6.00 | 157.00 | 43.00 |
| CommonStock | 118.00 | 6.00 | 157.00 | 32.00 |
| PreferredStock | 1.07M | 0.00 | 0.00 | 11.00 |
| TotalLiabilitiesNetMinorityInterest | 18.57M | 86.11M | 3.92M | 1.64M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 280.88K | 68.92M | 0.00 | 0.00 |
| OtherNonCurrentLiabilities | 864.00K | |||
| PreferredSecuritiesOutsideStockEquity | 0.00 | 64.24M | 0.00 | |
| EmployeeBenefits | 280.88K | 556.30K | 0.00 | |
| NonCurrentPensionAndOtherPostretirementBenefitPlans | 280.88K | 556.30K | 0.00 | |
| DuetoRelatedPartiesNonCurrent | 0.00 | 864.00K | 0.00 | |
| TradeandOtherPayablesNonCurrent | 0.00 | 0.00 | 0.00 | |
| NonCurrentDeferredLiabilities | 0.00 | 3.07M | 0.00 | 0.00 |
| NonCurrentDeferredTaxesLiabilities | 0.00 | 3.07M | 0.00 | |
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 193.15K | 0.00 | |
| LongTermCapitalLeaseObligation | 0.00 | 74.29K | 0.00 | |
| LongTermDebt | 118.86K | |||
| CurrentLiabilities | 18.29M | 17.19M | 3.92M | 1.64M |
| OtherCurrentLiabilities | 43.09K | 2.64K | 14.02K | |
| CurrentDebtAndCapitalLeaseObligation | 9.45M | 9.69M | ||
| CurrentCapitalLeaseObligation | 119.43K | 74.25K | 0.00 | |
| CurrentDebt | 9.33M | 9.62M | ||
| OtherCurrentBorrowings | 9.33M | 9.62M | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 186.96K | 487.58K | 1.13M | 234.26K |
| PayablesAndAccruedExpenses | 8.61M | 7.01M | 2.78M | 1.40M |
| CurrentAccruedExpenses | 662.03K | 1.65M | 1.10M | 821.25K |
| InterestPayable | 139.41K | 0.00 | ||
| Payables | 7.95M | 5.36M | 1.68M | 582.61K |
| DuetoRelatedPartiesCurrent | 4.12M | 0.00 | ||
| TotalTaxPayable | 40.00K | 60.53K | 177.60K | 0.00 |
| AccountsPayable | 3.79M | 5.30M | 1.50M | 582.61K |
| TotalAssets | 28.18M | 87.52M | 26.31M | 3.08M |
| TotalNonCurrentAssets | 27.23M | 81.68M | 52.71K | 11.50K |
| NonCurrentPrepaidAssets | 0.00 | 17.42K | 38.62K | 0.00 |
| NonCurrentDeferredAssets | 0.00 | 366.11K | 0.00 | |
| GoodwillAndOtherIntangibleAssets | 27.05M | 81.09M | 0.00 | |
| OtherIntangibleAssets | 25.41M | |||
| Goodwill | 27.05M | 55.68M | 0.00 | |
| NetPPE | 182.32K | 209.20K | 14.09K | 11.50K |
| GrossPPE | 182.32K | 209.20K | 14.09K | 11.50K |
| OtherProperties | 182.32K | 209.20K | 14.09K | 11.50K |
| CurrentAssets | 950.27K | 5.84M | 26.26M | 3.07M |
| CurrentDeferredAssets | 0.00 | 757.65K | ||
| PrepaidAssets | 143.38K | 770.15K | 469.23K | 234.55K |
| Inventory | 64.08K | 364.05K | 0.00 | |
| FinishedGoods | 6.63K | 30.04K | 0.00 | |
| WorkInProcess | 0.00 | 194.81K | 0.00 | |
| RawMaterials | 57.45K | 139.21K | 0.00 | |
| Receivables | 96.31K | 149.73K | 35.85K | 152.52K |
| OtherReceivables | 41.84K | |||
| DuefromRelatedPartiesCurrent | 0.00 | 35.85K | 152.52K | |
| TaxesReceivable | 28.76K | 0.00 | ||
| AccountsReceivable | 25.72K | 149.73K | 0.00 | |
| CashCashEquivalentsAndShortTermInvestments | 646.50K | 4.55M | 25.75M | 1.93M |
| CashAndCashEquivalents | 646.50K | 4.55M | 25.75M | 1.93M |
| CashFinancial | 646.50K | 4.55M | 25.75M | 1.93M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -10.52M | -13.64M | -8.68M | -2.05M |
| RepurchaseOfCapitalStock | -718.00 | -58.98K | -566.81K | 0.00 |
| RepaymentOfDebt | -1.35M | -1.00M | 0.00 | |
| IssuanceOfDebt | 5.00M | 0.00 | ||
| IssuanceOfCapitalStock | 3.48M | 2.30M | 34.87M | 0.00 |
| CapitalExpenditure | -28.47K | -55.04K | -9.34K | -1.92K |
| InterestPaidSupplementalData | 379.41K | 0.00 | ||
| EndCashPosition | 646.50K | 4.55M | 25.75M | 1.93M |
| BeginningCashPosition | 4.55M | 25.75M | 1.93M | 4.31M |
| EffectOfExchangeRateChanges | -126.66K | -3.33K | 0.00 | |
| ChangesInCash | -3.78M | -21.19M | 23.82M | -2.38M |
| FinancingCashFlow | 6.74M | 1.04M | 32.53M | -334.19K |
| CashFlowFromContinuingFinancingActivities | 6.74M | 1.04M | 32.53M | -334.19K |
| NetOtherFinancingCharges | -400.00K | -205.09K | -1.77M | -334.19K |
| ProceedsFromStockOptionExercised | 6.32K | 459.00 | 3.09K | 0.00 |
| NetPreferredStockIssuance | 2.80M | 2.30M | 0.00 | |
| PreferredStockIssuance | 2.80M | 2.30M | 0.00 | |
| NetCommonStockIssuance | 684.56K | -58.98K | 34.30M | 0.00 |
| CommonStockPayments | -718.00 | -58.98K | -566.81K | 0.00 |
| CommonStockIssuance | 685.28K | 0.00 | 34.87M | 0.00 |
| NetIssuancePaymentsOfDebt | 3.65M | -1.00M | 0.00 | |
| NetLongTermDebtIssuance | 3.65M | -1.00M | 0.00 | |
| LongTermDebtPayments | -1.35M | -1.00M | 0.00 | |
| LongTermDebtIssuance | 5.00M | 0.00 | ||
| InvestingCashFlow | -28.47K | -8.65M | -32.66K | -1.92K |
| CashFlowFromContinuingInvestingActivities | -28.47K | -8.65M | -32.66K | -1.92K |
| NetOtherInvestingChanges | -9.65M | -23.33K | ||
| NetBusinessPurchaseAndSale | 0.00 | 1.06M | 0.00 | |
| SaleOfBusiness | 0.00 | 1.06M | 0.00 | |
| NetPPEPurchaseAndSale | -28.47K | -55.04K | -9.34K | -1.92K |
| PurchaseOfPPE | -28.47K | -55.04K | -9.34K | -1.92K |
| OperatingCashFlow | -10.50M | -13.58M | -8.68M | -2.04M |
| CashFlowFromContinuingOperatingActivities | -10.50M | -13.58M | -8.68M | -2.04M |
| ChangeInWorkingCapital | -1.54M | 1.62M | 2.56M | 1.21M |
| ChangeInOtherWorkingCapital | -9.64K | |||
| ChangeInOtherCurrentAssets | -7.75K | -16.88K | -38.62K | |
| ChangeInPayablesAndAccruedExpense | -2.61M | 2.43M | 2.83M | 1.15M |
| ChangeInAccruedExpense | -1.13M | -942.08K | 1.74M | 809.28K |
| ChangeInPayable | -1.48M | 3.37M | 1.09M | 336.71K |
| ChangeInAccountPayable | -1.48M | 3.37M | 1.09M | 336.71K |
| ChangeInPrepaidAssets | 1.02M | -412.60K | -234.68K | 193.24K |
| ChangeInInventory | -62.27K | -315.83K | 0.00 | |
| ChangeInReceivables | 116.68K | -62.29K | 0.00 | -114.96K |
| ChangesInAccountReceivables | 116.68K | -62.29K | 0.00 | |
| OtherNonCashItems | 4.40M | 1.64M | 263.92K | |
| StockBasedCompensation | 438.65K | 329.76K | 1.97M | 130.14K |
| ProvisionandWriteOffofAssets | 0.00 | 1.15M | ||
| AssetImpairmentCharge | 46.51M | 18.45M | 0.00 | 22.24K |
| DeferredTax | -1.05M | -12.59K | 0.00 | |
| DeferredIncomeTax | -1.05M | -12.59K | 0.00 | |
| DepreciationAmortizationDepletion | 731.35K | 43.94K | 6.75K | 4.89K |
| DepreciationAndAmortization | 731.35K | 43.94K | 6.75K | 4.89K |
| Depreciation | 6.75K | 4.89K | ||
| OperatingGainsLosses | -1.30M | 595.84K | -61.41K | 1.20K |
| PensionAndEmployeeBenefitExpense | -48.42K | 13.88K | 0.00 | |
| GainLossOnInvestmentSecurities | -1.25M | 91.97K | -61.41K | |
| GainLossOnSaleOfPPE | 0.00 | 1.20K | ||
| NetIncomeFromContinuingOperations | -58.69M | -37.41M | -13.42M | -3.42M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ONCO
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|